TY - JOUR T1 - Diminished capacities to make treatment decision for COVID-19 vaccination in schizophrenia JF - medRxiv DO - 10.1101/2022.01.11.22269070 SP - 2022.01.11.22269070 AU - Stéphane Raffard AU - Sophie Bayard AU - Margot Eisenblaetter AU - Philippe Tattard AU - Jérôme Attal AU - Yasmine Laraki AU - Delphine Capdevielle Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/12/2022.01.11.22269070.abstract N2 - Recent evidence suggests that schizophrenia patients are at high risk for severe COVID-19 and should be prioritized for vaccination. However, impaired decision-making capacities could negatively affect the uptake of COVID-19 vaccination in this population. Competence to consent to COVID-19 vaccination was assessed in 80 outpatients with schizophrenia. Using the MacArthur Competence Assessment Tool for Treatment, 56.3% of the sample were classified as having diminished mental capacity. Poor performance was associated with lower vaccination rates, poorer cognition and higher level of psychotic symptoms. Developing interventions for enhancing informed consent for vaccination is urgent within this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was founded by a 2021 ANR Grant, (SCHIZOVAC; ANR-21-COVR-0017)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHU Montpellier, rRance IRB ID : 202100768I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -